semaglutide ema CHMP recommends label update to Novo Nordisk's Wegovy Ozempic Not Linked with Suicidal
Description
Lilly announces $3 billion expansion to injectable drug manufacturing facility for GLP-1 injectables
The findings are based on analysis of data from 2.4 million participants.
As the use of GLP-1 receptor agonists continues to expand for the treatment of type 2 diabetes and obesity, questions have emerged about their potential gastrointestinal side effectsparticularly gastroesophageal reflux disease (GERD)
Qualified scientific researchers
Prin susinerea microbiomului intestinal, contribuie la instalarea fireasc a saietii i la meninerea stabilitii glicemice, n contextul unui stil de via echilibrat
Suitable for pharmacokinetic and bioequivalence studies
